P787: SABATOLIMAB (MBG453) COMBINATION TREATMENT REGIMENS FOR PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES: THE MYELODYSPLASTIC SYNDROMES STUDIES IN THE STIMULUS IMMUNO-MYELOID CLINICAL TRIAL PROGRAM
HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 682-683
10.1097/01.hs9.0000846032.37876.c9